Hepatitis B Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Statistics, Revenue, Patient Pool, Prevalence and Companies DelveInsight

(Albany, USA) DelveInsight's "Hepatitis B Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Hepatitis B, historical and forecasted epidemiology as well as the Hepatitis B market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Hepatitis B market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hepatitis B treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hepatitis B market.

To Know in detail about the Hepatitis B market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatitis B Market Forecast @ https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Hepatitis B Market Report:
• On 12 Feb 2025 (Singapore Time), Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase 2 clinical trial. This significant progress further solidifies Lion TCR's leading position in the mRNA-based TCR-T field and brings new hope to patients with Hepatitis B virus related hepatocellular carcinoma (HCC).
• In January 2025:- Janssen Research & Development LLC:- A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection
• According to estimates provided by the Hepatitis B Foundation, National Foundation for Infectious Diseases (2018), and the CDC, the total number of chronic hepatitis B cases is estimated to be approximately 2.2 million or higher.
• In 2023, the United States recorded approximately 881,700 diagnosed prevalent cases of chronic hepatitis B.
• In the European Union's four largest countries plus the United Kingdom (EU4+UK), Germany had the highest diagnosed prevalence of chronic hepatitis B, totaling approximately 175,000 cases, whereas Spain had the lowest diagnosed prevalence, with around 52,500 cases in 2023.
• Key Hepatitis B Companies: Arbutus Biopharma, GSK/Ionis Pharmaceuticals, Vir Biotechnology, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp, Brii Biosciences Limited, Vir Biotechnology, Inc., Arbutus Biopharma Corporation, Erasmus Medical Center, Daewoong Pharmaceutical Co., Ascletis Pharmaceuticals, Gilead Sciences, Fujian Akeylink Biotechnology, Chia Tai Tianqing Pharma, Janssen Research & Development, LLC, Hoffmann-La Roche, Chengdu Suncadia Medicine, Suzhou Ribo Life Science, Arbutus Biopharma Corporation, Ascentage Pharma Group, and others
• Key Hepatitis B Therapies: AB-729, Bepirovirsen, Elebsiran, GSK3965193, DA-2803, ChAdOx1-HBV, Undiluted I.V.-Hepabig inj(GC5103), PEG-IFNα, VIR-3434, AB-729, ISA104, Vemliver tablet, ASC22, TAF, GST-HG131, TQA3605 tablets, JNJ-73763989, Nucleos(t)ide (NUC), HRS9950 tablets, RBD1016, Imdusiran, APG-1387, and others
• The Hepatitis B epidemiology based on gender analyzed that in 2023, there were more diagnosed prevalent cases of chronic hepatitis B (CHB) among males than females in the United States.
• The Hepatitis B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis B pipeline products will significantly revolutionize the Hepatitis B market dynamics.
• In March 2024, Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
• In February 2024, GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Fast track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Hepatitis B Overview
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is a major global health concern, particularly in regions such as sub-Saharan Africa and East Asia. The virus spreads through contact with infected blood, semen, or other body fluids, often via unprotected sex, needle sharing, or from mother to child during childbirth.
There are two forms of hepatitis B: acute and chronic. Acute infection occurs shortly after exposure and may be asymptomatic or present with symptoms such as jaundice, fatigue, abdominal pain, and nausea. While many people recover from acute hepatitis B without lasting liver damage, a subset develops chronic infection, especially if infected at birth or during early childhood. Chronic hepatitis B can lead to serious complications including liver cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer).
Hepatitis B Diagnosis is made through blood tests that detect HBV antigens and antibodies. Although there is no cure for hepatitis B, antiviral medications can suppress the virus and reduce liver damage in chronic cases. The most effective prevention strategy is vaccination, which offers long-term protection and has significantly reduced HBV incidence in countries with widespread immunization programs. Awareness, early diagnosis, and vaccination remain key to controlling hepatitis B globally.

Get a Free sample for the Hepatitis B Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hepatitis B Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hepatitis B Epidemiology Segmentation:
The Hepatitis B market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Hepatitis B
• Prevalent Cases of Hepatitis B by severity
• Gender-specific Prevalence of Hepatitis B
• Diagnosed Cases of Episodic and Chronic Hepatitis B

Download the report to understand which factors are driving Hepatitis B epidemiology trends @ Hepatitis B Epidemiology Forecast- https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hepatitis B Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis B market or expected to get launched during the study period. The analysis covers Hepatitis B market uptake by drugs, patient uptake by therapies, and sales of each drug.

Hepatitis B Therapies and Key Companies
• AB-729: Arbutus Biopharma
• Bepirovirsen: GSK/Ionis Pharmaceuticals
• Elebsiran: Vir Biotechnology
• GSK3965193: GlaxoSmithKline
• DA-2803: Dong-A ST Co., Ltd.
• ChAdOx1-HBV: Barinthus Biotherapeutics
• Undiluted I.V.-Hepabig inj(GC5103): GC Biopharma Corp
• PEG-IFNα: Brii Biosciences Limited
• VIR-3434: Vir Biotechnology, Inc.
• AB-729: Arbutus Biopharma Corporation
• ISA104: Erasmus Medical Center
• Vemliver tablet: Daewoong Pharmaceutical Co. LTD.
• ASC22: Ascletis Pharmaceuticals
• TAF: Gilead Sciences
• GST-HG131: Fujian Akeylink Biotechnology
• TQA3605 tablets: Chia Tai Tianqing Pharma
• JNJ-73763989: Janssen Research & Development, LLC
• Nucleos(t)ide (NUC): Hoffmann-La Roche
• HRS9950 tablets: Chengdu Suncadia Medicine
• RBD1016: Suzhou Ribo Life Science
• Imdusiran: Arbutus Biopharma Corporation
• APG-1387: Ascentage Pharma Group

Discover more about therapies set to grab major Hepatitis B market share @ Hepatitis B Treatment Landscape- https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hepatitis B Market Strengths
• The high prevalence of CHB is the primary strength of its global market, leading to more focus by pharmaceutical firms.
• New diagnostic biomarkers that help identify patients with CHB have been introduced for the diagnosis.

Hepatitis B Market Opportunities
• One of the major opportunities is the new diagnostic tools or methods that can be explored for the early detection of CHB in the affected patient's pool.
• Research work can be conducted to explore more of the conventional therapeutic (NAs) methods to reduce the side effects associated with the medications for CHB.

Scope of the Hepatitis B Market Report
• Study Period: 2019-2032
• Coverage: 7MM
• Key Hepatitis B Companies: Arbutus Biopharma Corporation (NASDAQ: ABUS), GSK plc (LSE: GSK), Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), Vir Biotechnology, Inc. (NASDAQ: VIR), Dong-A ST Co., Ltd. (KRX: 170900), Barinthus Biotherapeutics plc (NASDAQ: BRNS), GC Biopharma Corp (KRX: 006280), Brii Biosciences Limited (HKEX: 2137), Erasmus Medical Center (not publicly traded), Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), Ascletis Pharma Inc. (HKEX: 1672), Gilead Sciences, Inc. (NASDAQ: GILD), Fujian Akeylink Biotechnology Co. (not publicly traded), Chia Tai Tianqing Pharmaceutical Group (subsidiary of Sino Biopharmaceutical, HKEX: 1177), Janssen Research & Development, LLC (subsidiary of Johnson & Johnson, NYSE: JNJ), Hoffmann-La Roche Ltd (SWX: ROG), Chengdu Suncadia Medicine (not publicly traded), Suzhou Ribo Life Science Co., Ltd. (not publicly traded), and Ascentage Pharma Group International (HKEX: 6855).
• Key Hepatitis B Therapies: AB-729, Bepirovirsen, Elebsiran, GSK3965193, DA-2803, ChAdOx1-HBV, Undiluted I.V.-Hepabig inj(GC5103), PEG-IFNα, VIR-3434, AB-729, ISA104, Vemliver tablet, ASC22, TAF, GST-HG131, TQA3605 tablets, JNJ-73763989, Nucleos(t)ide (NUC), HRS9950 tablets, RBD1016, Imdusiran, APG-1387, and others
• Hepatitis B Therapeutic Assessment: Hepatitis B current marketed and Hepatitis B emerging therapies
• Hepatitis B Market Dynamics: Hepatitis B market drivers and Hepatitis B market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hepatitis B Unmet Needs, KOL's views, Analyst's views, Hepatitis B Market Access and Reimbursement

To know more about Hepatitis B companies working in the treatment market, visit @ Hepatitis B Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Hepatitis B Market Report Introduction
2. Executive Summary for Hepatitis B
3. SWOT analysis of Hepatitis B
4. Hepatitis B Patient Share (%) Overview at a Glance
5. Hepatitis B Market Overview at a Glance
6. Hepatitis B Disease Background and Overview
7. Hepatitis B Epidemiology and Patient Population
8. Country-Specific Patient Population of Hepatitis B
9. Hepatitis B Current Treatment and Medical Practices
10. Hepatitis B Unmet Needs
11. Hepatitis B Emerging Therapies
12. Hepatitis B Market Outlook
13. Country-Wise Hepatitis B Market Analysis (2020-2034)
14. Hepatitis B Market Access and Reimbursement of Therapies
15. Hepatitis B Market Drivers
16. Hepatitis B Market Barriers
17. Hepatitis B Appendix
18. Hepatitis B Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.